Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076332 | 0.79 | LTA4H (0.44) | MEN1KMT2ALTA4HPOLBPTGS1 | |
| SCHEMBL2092054 | 0.78 | SLC6A4 (0.56) | SLC6A4ALDH1A1CYP11B1CYP11B2TSHR | |
| SCHEMBL546118 | 0.77 | L3MBTL1 (0.57) | MEN1KMT2AATMLTA4HALDH1A1 | |
| SCHEMBL20738474 | 0.74 | MEN1 (0.61) | MEN1KMT2ALTA4HALDH1A1POLB | |
| SCHEMBL3236567 | 0.74 | HPGD (0.53) | POLBPTGS1PTGS2L3MBTL1SMN1; SMN2 | |
| SCHEMBL16770891 | 0.74 | SLC6A4 (0.58) | SLC6A4LTA4HALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL22621116 | 0.72 | SLC6A4 (0.51) | SLC6A4ALDH1A1CYP11B1CYP11B2TSHR | |
| SCHEMBL28508353 | 0.72 | L3MBTL1 (0.53) | MEN1KMT2ALTA4HPTGS1PTGS2 | |
| SCHEMBL45228 | 0.72 | LMNA (0.50) | ALDH1A1TSHRPOLBPTGS1PTGS2 | |
| SCHEMBL10526948 | 0.71 | LTA4H (0.52) | MEN1KMT2ALTA4HALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111763164-B | Preparation method and application of ortho-carbonyl amino substituted benzene derivatives | 中国医学科学院药物研究所 | 2023-03-10 | — | — | CN | disclosed |
| US-7002020-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY (US) | 2006-02-21 | — | — | US | disclosed |
| US-20050004174-A1 | Antibacterial agents | GORDEEV MIKHAIL F (US) | 2005-01-06 | — | — | US | disclosed |
| US-6562844-B2 | Attaching an olefin to a solid support; oxidizing the olefin to provide an epoxide functionality; opening the epoxide with an amine to form an amino alcohol; cyclizing the amino alcohol using a phosgene equivalent | PHARMACIA & UPJOHN COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-6531470-B1 | Antimicrobial compounds | PHARMACIA & UPJOHN COMPANY | 2003-03-11 | — | — | US | disclosed |
| US-6239152-B1 | Oxazolidinone combinatorial libraries, compositions and methods of preparation | PHARMACIA & UPJOHN COMPANY | 2001-05-29 | — | — | US | disclosed |
| US-6194416-B1 | CENTRAL NERVOUS SYSTEM DISORDERS; ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| US-6187776-B1 | AZACYCLIC-SUBSTITUTED PYRIDINE DERIVATIVES; ALZHEIMER*S DISEASE, SCHIZOPHRENIA, GASTROINTESTINAL DISORDERS; COGNITION ACTIVATORS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | disclosed |
| EP-0788489-A4 | HETEROCYCLIC COMPOUNDS AND THEIR USE | LILLY CO ELI (US) | 2000-11-15 | — | — | EP | disclosed |
| US-6071900-A | 2-AZABICYCLOOXYPYRIDAZINES TO TREAT DISEASES IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM; ALZHEIMER'S DISEASE; ANALGESICS; GI AND SLEEPING DISORDERS; GLAUCOMA, PSYCHOSIS, ANTIDEPRESSANTS | ELI LILLY AND COMPANY (US) | 2000-06-06 | — | — | US | disclosed |
| US-5998404-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0874828-A4 | COMPOSITION FOR TREATING PAIN | LILLY CO ELI (US) | 1999-09-01 | — | — | EP | disclosed |
| US-5888999-A | USING AZACYCLIC AND AZABICYCLIC PYRAZINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-30 | — | — | US | disclosed |
| EP-0874828-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1998-11-04 | — | — | EP | disclosed |
| EP-0788489-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE | ELI LILLY AND COMPANY (US) | 1997-08-13 | — | — | EP | disclosed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997017955-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0773027-A1 | Use of azacyclic or azabicyclic pyrazine compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-14 | — | — | EP | disclosed |
| WO-1996012711-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE | ELI LILLY AND COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004174-A1 | Antibacterial agents | PAICS, OXA1L, PNKP | MEN1 2807/4885KMT2A 1573/4885ATM 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.